Roche (OTCMKTS:RHHBY) Lifted to “Buy” at Bank of America

Bank of America upgraded shares of Roche (OTCMKTS:RHHBY) from a neutral rating to a buy rating in a research note released on Friday, Marketbeat Ratings reports.

A number of other brokerages also recently commented on RHHBY. Deutsche Bank Aktiengesellschaft raised shares of Roche from a sell rating to a hold rating in a research report on Friday, May 17th. The Goldman Sachs Group started coverage on Roche in a research report on Thursday, May 30th. They issued a sell rating for the company. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Roche currently has a consensus rating of Hold.

Roche Stock Up 1.0 %

Shares of OTCMKTS RHHBY opened at $39.11 on Friday. The company has a fifty day moving average price of $39.59 and a 200 day moving average price of $34.85. Roche has a 1-year low of $29.20 and a 1-year high of $42.43. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.75.

Institutional Investors Weigh In On Roche

Large investors have recently added to or reduced their stakes in the business. Altrius Capital Management Inc raised its position in shares of Roche by 6.0% during the second quarter. Altrius Capital Management Inc now owns 224,804 shares of the company’s stock worth $7,794,000 after purchasing an additional 12,646 shares during the period. Archer Investment Corp boosted its holdings in Roche by 10.6% during the 2nd quarter. Archer Investment Corp now owns 6,810 shares of the company’s stock worth $236,000 after acquiring an additional 652 shares during the last quarter. Rhumbline Advisers increased its stake in Roche by 0.9% in the 2nd quarter. Rhumbline Advisers now owns 103,985 shares of the company’s stock valued at $3,605,000 after buying an additional 904 shares during the last quarter. Waldron Private Wealth LLC purchased a new position in Roche in the second quarter worth $263,000. Finally, Hantz Financial Services Inc. bought a new position in Roche during the second quarter valued at about $1,164,000.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.